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As a non-steroidal anti-oestrogen, tamoxifen (TAM) is frequently
used as endocrine therapy for human breast cancer (Tormey et al,
1976; Robinson and Jordan, 1988; Lerner and Jordan, 1990), and
whilst it is effective in many patients (approximately two-thirds of
oestrogen receptor (ER)-rich patients), the majority of unselected
cancers appear resistant, with those which do respond to therapy
eventually relapsing (Raam et al, 1988; Gottardis et al, 1989;
Graham et al, 1990; Scott et al, 1991; Osborne et al, 1991, 1992;
Wolf et al, 1993; Horwitz, 1993).
Resistance to TAM therapy may be due to a single, or a combi-
nation of several factors including; down-regulation or loss of
oestrogen receptors (Miller et al, 1984; Raam et al, 1988; Murphy
and Dozlaw, 1989; Graham et al, 1990; Foster et al, 1991; Scott et
al, 1991; Horwitz, 1993); altered production of growth factors
such as transforming growth factor beta (TGF-b) (Miller et al,
1984; Koga and Sutherland, 1987); altered signal transduction 
and increased expression of anti-oestrogen binding sites (AEBSs)
which may directly mediate anti-oestrogen actions (Murphy 
and Sutherland, 1981; Miller and Katzenellenbogen, 1983).
Pharmacological mechanisms such as a shift in metabolism,
producing isomers (Wolf et al, 1993) or oestrogenic metabolites,
and changes in levels of drug accumulation within tumour tissues
(Osborne et al, 1987, 1991, 1992) may additionally be important.
Although significant differences in levels of circulating TAM
and metabolites have not been reported between responding and
resistant tumours (Johnstone et al, 1993; MacCallum et al, 1996),
TAM resistance and stimulation of growth may be associated with
a reduction in intra-tumoural TAM levels (Gottardis and Jordan,
1988; Osborne et al, 1991, 1992), with stimulation of growth on
increasing concentrations in a dose-dependent manner (Gottardis
et al, 1989). In breast cancer patients, TAM and its metabolites
accumulate in tumour tissue when compared to serum or plasma
(Daniel et al, 1981; Lien et al, 1991a, 1991b), and intra-tumoural
levels thus do not necessarily reflect those in the circulation.
Having developed a rapid, sensitive and selective solid-phase
extraction (SPE) and a high-performance liquid chromatography
(HPLC) separation method for the determination of TAM and its
major metabolites in plasma (MacCallum et al, 1996) and tumour
(MacCallum et al, 1997) tissue, the aim of the present study was to
correlate levels in tumour tissue and plasma with response to TAM
therapy in a group of breast cancer patients.
MATERIALS AND METHODS
TAM base (z-type isomer), cis-TAM (CIS, e-type isomer) and
metabolites 4OH and DMT were generously supplied by Zeneca
Pharmaceuticals (Macclesfield, UK). [N-methyl-3H]TAM was
obtained from Amersham International (Little Chalfont, UK).
Standard solutions were prepared in methanol (MeOH) and stored
at 4°C. MeOH and acetonitrile (ACN) were of HPLC-reagent grade
(Rathburn Chemicals, Walkerburn, UK); triethylamine (TEA) and
sodium chloride (NaCl) were obtained from Sigma (Poole, UK)
and dimethylsulphoxide (DMSO) was analytical grade (Fisons,
Loughborough, UK). Water was deionized and bi-distilled in a
milli-U10 water purification system (Millipore, Harrow, UK).
Solid-phase extraction was carried out on Bond-elut C2 3-cm3
columns (Varian sample preparation products, Phenomenex,
Macclesfield, UK). The HPLC stationary phase was mbondapak C18
(125Å, 10 mm) packed in a 30 cm ´ 3.9 mm I.D. stainless steel
column with a 1 cm C18 guard column (Waters, Watford, UK).
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The chromatography systems used are detailed in MacCallum et al
(1996, 1997). For plasma measurement the mobile phase consisted
of 1% TEA (in dH2O, pH 8.0) in MeOH (11:89, v/v), and for
tumour measurement of 1% TEA (in dH2O, pH 9.0) in MeOH
(11:89, v/v). Mobile phase components were passed through a
0.22 mm filter and degassed prior to use. Elution was isocratic at a
flow-rate of 1.2 ml min–1 at ambient room temperature.
Patient data
Samples were obtained from patients treated in the Edinburgh
Breast Unit. Plasma and primary tumour tissue was obtained at
surgery from 54 post-menopausal, ER-rich (> 20 fmol mg–1
cytosol protein) breast cancer patients treated with tamoxifen for
at least 3 months (range 3–86 months). Response at 3 months and
at surgery (if > 3 months) was monitored by monthly ultrasound
and clinical measurement of the tumour. Patients were classified as
responding where tumour volume decreased by at least 25%
between initial biopsy and the chosen timepoint (3 months and
surgery), whilst non-responders showed either no change (< 25%
increase or < 25% decrease in volume) or an increase (> 25%) in
tumour volume (Forouhi et al, 1994).
Patients were then categorized according to response of their
tumour throughout treatment. Thus, tumours decreasing in size
with continual reduction or decreasing then showing no change
thereafter were considered to be responders (R-R, n = 25); those
initially reducing in size but which later increased in size were
considered to have developed acquired resistance to tamoxifen (R-
NR, n = 22; minimum length of treatment 4 months); and tumours
remaining the same size or increasing in size on treatment were
considered to show de novo resistance (NR-NR, n = 6).
Sample preparation
This was carried out as detailed in MacCallum et al (1996, 1997).
Briefly, 1 ml aliquots of plasma, and 0.5 mg aliquots of tumour
tissue (all tissue available was dismembrated and 0.5 mg aliquots
resuspended in DMSO), were spiked with radioinert CIS (and 3H
TAM in the case of tumour tissue) in order to monitor extraction
efficiency. Aliquots were then applied to an activated solid-phase
extraction column, which was washed through with dH2O,
dH2O:MeOH (50:50) and ACN. Elution was with 1 M NaCl:
MeOH (5:95, v/v). Samples were then dried, resuspended and
analysed by HPLC. For tumour tissue, an aliquot of the resus-
pended eluent was placed into scintillant to count 3H TAM for an
additional calculation of recovery.
Analyses were carried out in duplicate in the presence of blank
plasma and tumour samples, spiked plasma and tumours samples
and standards in MeOH as controls. Multiple analyses were
carried out to determine reproducibility. Accuracy (± precision)
was 111–168% (± 43–63%) for plasma measurement at 10 ng ml–1,
and 63–94% (± 13–26%) for tumour measurement at 20 ng g–1.
Plasma measurements showed a tendency for overestimation at
lower concentrations, with greater accuracy at higher concentra-
tions (98–109% ± 5–10% at 1 mg ml–1), although there was still a
tendency for overestimation of 40H levels.
Concentrations of plasma and tumour were calculated from the
peak areas measured by HPLC (Figure 1), and normalized to
100% taking into account extraction efficiency and any day-to-day
alteration (monitored via spiked samples), and were expressed 
as ng ml–1 of plasma and ng g–1 of tissue. Extraction efficiency 
(± between-day variation) was 59–64% (±2.4–14.5%) at 2 ng ml–1
for plasma measurements and 60–64% (±16–20%) at 20 ng g–1 for
tumour measurements.
Statistical analysis
Levels of TAM, 4OH and DMT in blood and tumour tissue were
calculated as described previously (MacCallum et al, 1996, 1997),
and statistical analysis was carried out to determine associations
between metabolite levels and: length of time on tamoxifen;
response to tamoxifen at 3 months, final surgery and overall; and
weight of patient at presentation (where available). In addition,
tumour:plasma ratios were correlated with time and response; and
the possible effects of tumour cellularity were examined by corre-
lation with ER values.
Analyses on the mean concentrations of each metabolite were
carried out using non-parametric tests, as the data were not
normally distributed. Tests included Spearman rank,
Mann–Whitney, Kruskal–Wallis and Pearson tests, correlation and
regression analysis.
RESULTS
Levels of TAM, 4OH or DMT in blood plasma and tumour tissue
were correlated with treatment time in both a continuous manner,
and additionally using arbitrary time divisions (< 5 months, 5–11
months and > 11 months of treatment) (Table 1). Although there
was no significant accumulation of plasma or tumour TAM or
DMT levels with time, levels of 4OH in tumour tissues showed 
a tendency to increase with increasing time on TAM
(Kruskal–Wallis,  P = 0.066), whilst tumours from patients
receiving < 5 months of treatment were found to contain signifi-
cantly less 4OH when compared to those receiving > 11 months of
treatment (Mann–Whitney, P = 0.02). Additionally, in those
patients showing overall acquired resistance to tamoxifen, there
was significant accumulation of 4OH continuously over treatment
1630 J MacCallum et al
British Journal of Cancer (2000)  82(10), 1629–1635 © 2000 Cancer Research Campaign
1
2
3 4
4
.
1
8
5
.
4
9
7
.
0
4
2
8
.
8
2
1
1
.
0
2
1
1
.
0
0
5
.
9
Figure 1 An example of an HPLC trace, obtained from a tumour sample
prepared by solid-phase extraction. Peaks relate to: 1 = 4OH; 2 = DMT; 
3 = TAM; 4 = CIS (cis-isomer of tamoxifen). Drug levels are calculated from
the measured area under each peakduration (R-NR, Spearman rank, P = 0.017) (Figure 2). In contrast,
plasma concentrations of 4OH were found to be significantly
higher in the 5–11 months treatment group, when compared to the
other arbitrary groupings (Mann–Whitney, P = 0.04, Table 1).
All patients were treated with the same dose of TAM (20 mg
day–1). However, there is evidence from an overlapping study on
patients treated at the Edinburgh Breast Unit, that there is a corre-
lation between TAM levels and weight, especially in the upper
quartile (Love et al, 1997). Thus, where available (n = 32), we
examined patient weight (kg) at time of presentation in association
with TAM and metabolite levels. There were no significant corre-
lations between weight and levels of 4OH or DMT although TAM
levels did show a tendency to increase with increasing weight and
time in tumours exhibiting acquired resistance (R-NR, regression
analysis, r = 0.03). When patients were divided arbitrarily into
three groups; < 63, 63–69 and > 69 kg initial weight, again no
significant differences were apparent (Table 1). Further, when
weight was taken into account, mean concentrations of TAM, 4OH
and DMT in plasma (ng ml–1 kg–1) and tumour (ng g–1 kg–1) showed
no significant differences between the three response groups.
Where levels of TAM, 4OH and DMT in tumour were corre-
lated with response after 3 months of treatment, and at surgery,
there were no significant differences between tumours which
either responded or did not respond to TAM (Table 2). However,
similarily grouped plasma levels showed differences between
responding and non-responding patients after 3 months of TAM.
Plasma levels of 4OH and DMT were significantly higher in non-
responding patients (Mann–Whitney, P = 0.05, P = 0.03). No such
differences were seen for TAM after 3 months of treatment, or for
any of the three species in plasma taken at surgery.
Patients were additionally grouped according to overall tumour
response (Table 3). Once again, no significant differences were
seen in plasma or tumour levels of TAM, 4OH or DMT in relation
to response type, the exception being significantly higher levels 
of DMT in the plasma of the de novo resistant group when
compared to the responding group (Mann–Whitney, P = 0.03).
Tumour:plasma ratios were calculated to evaluate tumour accumu-
lation of TAM, but once again no significant differences were seen
between response groups.
To examine the inter-relationships between metabolite levels,
tumour concentrations of each metabolite were plotted against
each of the others. On doing this we noted significant associations
between TAM and 4OH in de novo resistant tumours, and between
TAM and DMT in responding and acquired resistance tumours
(Figure 4).
Levels of TAM and metabolites were wide-ranging throughout
the group of patients, which may reflect the large heterogeneity of
breast cancers, and the presence of areas of non-neoplastic cells
within our tissue samples. Whilst we attempted to minimize this
effect during our sample preparation, we were unable to correct
entirely for differences in tissue cellularity. ER values (fmol mg–1
cytosol protein), were known in 41 samples. No correlations were
evident with metabolite levels (mg ml–1 or mg g–1) (data not
shown). Interestingly, two samples taken from involved lymph
nodes were available, in both of which concentrations of TAM,
4OH and DMT had accumulated to very high levels (Table 3).
Other samples examined included a number of mucoid
cancers, in which cases, response to treatment is difficult to
ascertain by clinical and ultrasound measurement. No signifi-
cant differences in concentrations of TAM, 4OH and DMT were
noted when comparing the three response groups (Table 3).
Additionally a small number of samples were available from
ER-poor patients who had received short-term TAM therapy
(Table 3). Tumour metabolite levels did not differ significantly
from the other response groups, however, whilst 4OH plasma
levels did not differ greatly in the three main response group-
ings, levels in ER-poor patient plasmas were significantly lower
than all other subgoupings (apart from mucoid tumours)
Tamoxifen and response 1631
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Table 1 Correlations with length of treatment and initial patient weight
4OH DMT TAM
Tumour Plasma Tumour Plasma Tumour Plasma
(ng g–1) (ng ml–1) (ng g–1) (ng ml–1) (ng g–1) (ng ml–1)
All patients  (n = 54) 156 (± 134) 67 (± 34) 569 (± 689) 235 (± 116) 331 (± 250) 115 (± 63)
< 5 (n = 15) 92 (± 79) 57 (± 22) 612 (± 911) 231 (± 97) 331 (± 181) 116 (± 43)
5–11 (n = 19) 159 (± 129) 79 (± 28) 443 (± 484) 239 (± 84) 302 (± 220) 115 (± 56)
> 11 (n = 20) 200 (± 156) 60 (± 41) 657 (± 681) 241 (± 151) 358 (± 322) 124 (± 74)
Initial weight (kg)
All patients (n = 34) 147 (± 120) 65 (± 28) 611 (± 831) 235 (± 98) 326 (± 247) 115 (± 48)
< 63 (n = 12) 132 (± 118) 68 (± 31) 257 (± 232) 247 (± 116) 273 (± 122) 139 (± 48)
63–69 (n = 8) 129 (± 90) 64 (± 15) 624 (± 919) 226 (± 92) 345 (± 322) 102 (± 44)
> 69 (n = 13) 174 (± 141) 63 (± 34) 857 (± 1086) 245 (± 79) 367 (± 293) 99 (± 43)
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Figure 2 Tissue levels of 4OH in tumours showing acquired resistance
plotted against length of time of treatment (n = 22, P = 0.017)
Time on TAM
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Table 2 Mean levels of TAM, 4OH and DMT in responding (R) and non-
responding (NR) patient plasma and tumour after 3 months of treatment, and
at final surgery
3 months treatment Final surgery
Tumoura R (n = 47) NR (n = 6) R (n = 25) NR (n = 28)
4OH 157 (± 137) 145 (± 118) 138 (± 107) 171 (± 154)
DMT 589 (± 733) 436 (± 215) 610 (± 875) 534 (± 489)
TAM 340 (± 265) 273 (± 100) 334 (± 233) 327 (± 268)
Plasmab
4OH 68 (± 35) 74 (± 23) 66 (± 30) 80 (± 78)
DMT 227 (± 116) 313 (± 80) 224 (± 98) 242 (± 123)
TAM 117 (± 63) 131 (± 30) 118 (± 58) 115 (± 58)
a ng g–1 ± s.d. bng ml–1 ± s.d.
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Figure 3 Overall response to tamoxifen therapy plotted against drug 
levels. (A) = 4OH; (B) = DMT; (C) = TAM. Columns relate to tissue levels
(mean ± s.d.): 1 = response; 2 = acquired resistance; 3 = de novo resistance;
4 = mucoid pathology; 5 = ER-poor status; 6 = Lymph nodes
Figure 4 Inter-relationships between metabolites. (A) TAM vs 4OH in de
novo resistant tumours (r = 0.591); (B) TAM vs DMT in responding tumours 
(r = 0.598); (C) TAM vs DMT in acquired resistance tumours (r = 0.802)
Figure 4 Inter-relationships between metabolites. (A) TAM vs 4OH in de
novo resistant tumours (r = 0.591); (B) TAM vs DMT in responding tumours 
(r = 0.598); (C) TAM vs DMT in acquired resistance tumours (r = 0.802)
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B(Mann–Whitney, P = 0.01–0.03). Similarily, levels of DMT in
ER-poor patient plasmas were significantly lower than in both
responding and de novo resistant patients (Mann–Whitney, 
P = 0.03, P = 0.0003), whilst TAM levels in this group were
significantly less than those in the de novo resistant group
(Mann–Whitney,  P = 0.01).
DISCUSSION
The aim of this study was to measure levels of TAM, 4OH and
DMT in plasma and tumour tissue taken from patients undergoing
primary neoadjuvant therapy with TAM, and to correlate these
with the response of individual tumours to treatment. After an
initial tumour biopsy, patients were treated with TAM for at least 3
months, during which time the response of the remaining tumour
was monitored. Thus, we have been able to subdivide patients not
only as to whether their tumours exhibited resistance to TAM or
not, but also whether this was de novo, or acquired resistance. We
hoped to discover if differences in levels of TAM and its major
metabolites could account for differences in tumour response.
Levels of TAM and metabolites in both plasma and tumour
tissue compared well with those previously reported, although
there was a tendency for levels of 4OH and DMT to be somewhat
higher than those detected by other investigators (Daniel et al,
1979; Robinson et al, 1989; Langan-Fahey et al, 1990; Lim et al,
1993; MacCallum et al, 1997). There could be several explana-
tions for this: from recovery of spiked plasmas, 4OH as the first
metabolite off the HPLC column was seen to be the metabolite
most likely to be contaminated with spurious peaks, thus overesti-
mation of plasma levels of all three metabolites, most especially
4OH (as the metabolite present at the lowest concentrations) is a
possibility. Alternatively, high levels of this metabolite could
reflect differences in patient population (taking into account those
patients with responding as well as non-responding tumours); with
many patients undergoing long-term TAM therapy, levels could
reflect accumulation of 4OH with time, for which there is some
evidence with regard to tumour tissue (Table 1 and Results),
particularily in RNR patients (Figure 2).
On statistical analysis, where tumour levels of TAM, 4OH and
DMT were correlated with response to therapy, whether at 3
months, at the time of final surgery or overall, there were no signif-
icant differences which would account for the development of
resistance to TAM, although differences in the mean and median
levels of each metabolite did exist. However, the range of values in
each group was wide (see Tables 1–3), thereby nullifying the
statistical strength of these differences. Whilst this is a likely
reflection of the reproducibility of our assay (as constrained by
tissue availability), it may also reflect the heterogeneity of breast
tumours, and could relate to tumour cellularity. Whilst we
attempted to minimize the effects of heterogeneity, we were unable
to correct for cellularity within our sample group. It is interesting
to note that high levels of metabolites were found in two lymph
node metastases sampled (Table 3), as these are highly cellular.
Investigations on inter-relationships between metabolites
carried out by plotting the tumour concentration of one against the
others show some interesting data (Figure 4.). Concentrations of
TAM and 4OH were significantly associated in de novo resistant
tumours, suggesting that levels of TAM in these tumours could
indicate similar trends in levels of 4OH, whilst responding and
acquired resistance tumours showed significant associations
between TAM and DMT levels. These results could indicate
fundamental differences in the metabolism of TAM within the
different response groups.
On analysis of plasma levels, some significant differences were
noted, particularily after 3 months of TAM treatment. At this time,
plasma levels of both 4OH and DMT in responding patients were
found to be significantly lower than those in non-responding
patients (Table 2), whilst plasma DMT levels were significantly
higher in de novo resistant patients when compared to responding
patients (Table 3). These differences could indicate increased
metabolism of TAM in non-responding patients, or increased
uptake of these metabolites into tumour tissues in responding
patients. Certainly, there is evidence for accumulation of 4OH in
tumour tissues of the acquired resistance group with increasing
treatment time.
Our results are contrary to the decreased accumulation of
tamoxifen found in tumours showing acquired resistance, which
has been reported by several investigators (Osborne et al, 1987,
1991, 1992; Johnstone et al, 1993). There could be several reasons
for this. We mention previously that differences in the population
of patients involved in the study, with the inclusion of both
responding and non-responding patients, may have had an effect,
and we have not involved ER-poor patients in the whole analysis
as others have. The inclusion in the present study of a substantial
number of patients on long-term TAM therapy may confound,
hiding the predominantly short-term effects reported on previ-
ously.
On analysis of a small number of ER-poor patients (n = 8, 1–3
months TAM), we found significantly lower plasma levels of each
metabolite when compared to certain of the other response groups
(Table 3 and Results). This could be indicative of the short TAM
treatment given to these patients, although there is no such
Tamoxifen and response 1633
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Table 3 Mean levels of TAM and metabolites in plasmas and tumour tissues from patients correlated with overall response to therapy
Tumoura RR (n = 25) RNR (n = 22) NRNR (n = 6) LN (n = 2) Mucoid (n = 8) ER (n = 8)
4OH 138 (± 107) 179 (± 165) 115 (± 96) 960 (± 739) 131 (± 134) 115 (± 122)
DMT 610 (± 875) 566 (± 549) 427 (± 234) 3989 (± 438) 346 (± 335) 586 (± 604)
TAM 335 (± 233) 345 (± 303) 272 (± 110) 1054 (± 37) 249 (± 215) 399 (± 340)
Plasmab
4OH 68 (± 30) 64 (± 40) 74 (± 23) 59 (± 53) 69 (± 34) 33 (± 26)
DMT 224 (± 98) 230 (± 135) 313 (± 80) 562 (± 620) 194 (± 121) 136 (± 61)
TAM 118 (± 58) 116 (± 70) 131 (± 30) 207 (± 239) 106 (± 87) 68 (± 39)
ang g–1 ± s.d. bng ml–1 ± s.d.evidence for such low levels of plasma in ER-rich patients
receiving equally brief treatment (Table 1, < 5 months treatment).
Indeed, it is thought that steady-state levels of the drug are
reached within 1 month of treatment (Langhan-Fahey et al, 1990;
Robinson and Jordan, 1994). Although ER-poor tumour levels
were seen to be compatable with the other groups, low levels in
plasma may indicate differences in uptake or metabolism of 
TAM in these patients from the commencement of treatment.
Certain markers of tumour growth can be examined and proven
predictive of response prior to the achievement of steady-state
TAM levels (Cameron et al, 1997). Early differences in levels of,
or accumulation of, TAM and metabolites may yet prove to be of
importance.
Where tumour levels were evaluated against overall response, no
significant differences in uptake were noted which would account
for differences in response. However, where length of treatment
was also considered, tumour tissue 4OH levels accumulated signi-
ficantly over time (Table 1 and Results), especially in the subset of
tumours showing acquired resistance (Figure 2). As these patients
had undergone prolonged TAM therapy, this could indicate a slow
change within the tumour, such as clonal expansion of resistant
cells, or a change in tumour cell adaptive processes thereby causing
a switch from response to resistance in the presence of a highly
potent anti-oestrogen (100–1000 times stronger than TAM).
In a previous study involving an overlapping group of patients
treated at the Edinburgh Breast Unit, there was evidence of a
correlation between TAM levels and weight (Love et al, 1997),
although no previous correlations between TAM or DMT levels
and obesity have been found (Langhan-Fahey et al, 1990).
Analysis of the data for patients whose weight at presentation 
was known, and for whom a ratio of tumour or plasma concentra-
tion kg–1 was produced, showed no significant differences between
response groups.
In this study we did not set out to obtain evidence for tamoxifen-
stimulated tumour growth, such as measuring the amount of
metabolite E (Osborne, 1995), as we were looking for differences
in metabolism or drug accumulation which could account for
resistance to therapy. From our study, it would appear that knowl-
edge of tumour levels of TAM, 4OH and DMT does not correlate
with response to TAM therapy. In certain subgroups of our study
group, both plasma and tumour levels may indeed have relevance
to response, if taken in combination with other factors such as
length of treatment.
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